Cardiac Xenotransplantation Overview

Principles

Definition

Cardiac xenotransplantation is an interdisciplinary research field and clinical approach focused on the transplantation of a heart from one species into another, predominantly from genetically modified non-human animals to human recipients. This domain investigates strategies to mitigate immunological rejection and physiological incompatibilities, aiming to provide a viable solution for end-stage heart failure in the context of severe human donor organ scarcity.

Ontological type

Immunological Barriers

Genetic Engineering Strategies

Clinical Outcomes

Key developments

Key Figures

Immunomodulatory Foundation era

Jeffrey L. Platt [1] is associated with the University of Pennsylvania [3] and Columbia University [4] during the Immunomodulatory Foundation era (1987-1993). His key contribution in this era is the immunopathology study IMMUNOPATHOLOGY OF HYPERACUTE XENOGRAFT REJECTION IN A SWINE-TO-PRIMATE MODEL [7], which illuminated the immune processes driving xenograft rejection and underscored the need for immunomodulatory regimens. Arthur J. Matas [2] is linked to University of California, San Francisco [5] and Stanford University [6] during this era. His principal contribution in this era centers on IMMUNOPATHOLOGY OF HYPERACUTE XENOGRAFT REJECTION IN A SWINE-TO-PRIMATE MODEL [7], whose findings informed the design of immunomodulatory strategies and essential surveillance methods that defined the era.

Genetic Complement Engineering era

Jeffrey L. Platt [1] is associated with Harvard University [3] and Princeton University [4] during the Genetic Complement Engineering era. His work on human complement regulatory proteins protecting swine-to-primate cardiac xenografts from humoral injury [6], on transgenic pigs expressing human CD59 and decay-accelerating factor producing an intrinsic barrier to complement-mediated damage [7], and on the role of antibodies in acute vascular rejection of pig-to-baboon cardiac transplants [8] defined how genetic modifications could counteract humoral and complement-mediated barriers in this era. John S. Logan [2], with Johns Hopkins University [5] and Princeton University [4], participated in this research during the era. Logan's key contributions include highlighting the role of antibodies in acute vascular rejection [8], and supporting strategies to block humoral injury through complement-regulatory approaches such as CD59 and DAF interventions [6][7], which helped establish antibodies and complement as central barriers to xenograft survival in this era.

Endothelial-Coagulation Focus era

Akira Shimizu[1] is a researcher active in the Endothelial-Coagulation Focus era (2004–2010), with affiliations to Harvard University[3] and Boston University[4] during this period. In this era, his key contribution is illustrated by the paper Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience[6], which reports initial baboon heart transplants from α1,3-galactosyltransferase gene-knockout pigs and highlights the feasibility and endothelial-coagulation considerations of xenotransplantation. Kazuhiko Yamada[2] is another figure in this era, with ties to Harvard University[3] and Harbin Medical University[5]. His key contribution, as reflected in the same paper Heart transplantation in baboons using α1,3-galactosyltransferase gene-knockout pigs as donors: initial experience[6], contributed to documenting the early pig-to-primate xenotransplantation experience that informed the endothelial-coagulation paradigm and preclinical assessment in this era.